These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1429329)

  • 21. Activity of daptomycin against gram-positive bacterial isolates from Indian medical centres (2006-2007).
    Mathai D; Biedenbach DJ; Jones RN; Bell JM; Turnidge J; Sader HS;
    Int J Antimicrob Agents; 2009 Nov; 34(5):497-9. PubMed ID: 19619989
    [No Abstract]   [Full Text] [Related]  

  • 22. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens.
    Cornaglia G; Rossolini GM
    Clin Microbiol Infect; 2009 Mar; 15(3):218-23. PubMed ID: 19335369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. National guidelines for the judicious use of glycopeptides in Belgium.
    Gordts B; Firre E; Jordens P; Legrand JC; Maertens J; Struelens M;
    Clin Microbiol Infect; 2000 Nov; 6(11):585-92. PubMed ID: 11168061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oritavancin microbiologic features and activity results from the surveillance program in the United States.
    Mendes RE; Farrell DJ; Sader HS; Jones RN
    Clin Infect Dis; 2012 Apr; 54 Suppl 3():S203-13. PubMed ID: 22431850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of in vitro activity of teicoplanin against recent clinical isolates.
    Nani E; Amato G; Anzivino D; Covelli B; Lembo M
    Chemioterapia; 1988 Feb; 7(1):20-3. PubMed ID: 2967737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction of teicoplanin with other antimicrobial agents against gram-positive aerobes.
    Watt B
    J Antimicrob Chemother; 1989 Apr; 23(4):657-8. PubMed ID: 2526113
    [No Abstract]   [Full Text] [Related]  

  • 27. In vitro activity of tedizolid and comparator agents against clinical Gram-positive isolates recovered from patients with cancer.
    Rolston KVI; Reitzel R; Vargas-Cruz N; Shelburne SA; Raad II; Prince RA
    Diagn Microbiol Infect Dis; 2018 Aug; 91(4):351-353. PubMed ID: 29661529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative in vitro activities of daptomycin, vancomycin, teicoplanin and linezolid against resistant Gram-positive bacterial isolates from two large centres in western India.
    Biswas S; Watwani J; Vadwai V; Shetty A; Kelkar R; Rodrigues C
    Int J Antimicrob Agents; 2012 Dec; 40(6):567-9. PubMed ID: 22947124
    [No Abstract]   [Full Text] [Related]  

  • 29. In vitro activities of tigecycline, daptomycin, linezolid and quinupristin/dalfopristin against glycopeptide-resistant Enterococcus faecium.
    Abb J
    Int J Antimicrob Agents; 2007 Mar; 29(3):358-60. PubMed ID: 17229553
    [No Abstract]   [Full Text] [Related]  

  • 30. In vitro activity of A-16686, a new glycopeptide.
    Neu HC; Neu NM
    Chemotherapy; 1986; 32(5):453-7. PubMed ID: 3757587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.
    Poulakou G; Giamarellou H
    Expert Opin Investig Drugs; 2008 Feb; 17(2):225-43. PubMed ID: 18230056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging Roles of Glycopeptide Antibiotics: Moving beyond Gram-Positive Bacteria.
    Acharya Y; Bhattacharyya S; Dhanda G; Haldar J
    ACS Infect Dis; 2022 Jan; 8(1):1-28. PubMed ID: 34878254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres.
    Gales AC; Sader HS; Jones RN
    Clin Microbiol Infect; 2005 Feb; 11(2):95-100. PubMed ID: 15679482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Urinary infection. II. Comparative in vitro activities of several antibiotic drugs against Gram-positive bacteria].
    Allocco A; Giachino F; Tuninetti L; Tullio V; Cuffini AM; Carlone NA
    G Batteriol Virol Immunol; 1992 Jan-1993 Dec; 85(1-12):68-78. PubMed ID: 7498618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
    Jansen WT; Verel A; Verhoef J; Milatovic D
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3420-4. PubMed ID: 17606689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycopeptide resistance in enterococci.
    Méndez-Alvarez S; Pérez-Hernández X; Claverie-Martín F
    Int Microbiol; 2000 Jun; 3(2):71-80. PubMed ID: 11001535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversibility of antimicrobial resistance in respiratory isolates in HIV-positive Cambodian children after 36 months of HAART.
    Shahum A; Benca G; Duong LS; Augustin A; Havlik S; Liska A; Kalavsky E; Beno P; Krcmery V
    J Antimicrob Chemother; 2007 Jul; 60(1):194-7. PubMed ID: 17545143
    [No Abstract]   [Full Text] [Related]  

  • 38. Anaerobes: antibiotic resistance, clinical significance, and the role of susceptibility testing.
    Hecht DW
    Anaerobe; 2006 Jun; 12(3):115-21. PubMed ID: 16765857
    [No Abstract]   [Full Text] [Related]  

  • 39. Current perspectives on glycopeptide resistance.
    Woodford N; Johnson AP; Morrison D; Speller DC
    Clin Microbiol Rev; 1995 Oct; 8(4):585-615. PubMed ID: 8665471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Tolerance and heteroresistance in Gram-positive microorganisms].
    Morosini MI; Cantón R
    Med Clin (Barc); 2010 Dec; 135 Suppl 3():16-22. PubMed ID: 21477700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.